Intravacc
Antonie van Leeuwenhoeklaan 9
MA Bilthoven
3721
Tel: 31-0-30-2744004
Website: http://www.intravacc.nl/
Email: info@intravacc.nl
23 articles about Intravacc
-
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
3/28/2024
Intravacc and Primrose Bio announced a strategic partnership to enhance the development and supply of conjugate vaccines.
-
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
3/26/2024
Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, announced positive clinical data of a first in human study of Avacc 10®, an intranasal outer membrane vesicles based booster vaccine for SARS-CoV-2.
-
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
1/16/2024
Intravacc announced that it has been awarded a funding that may total US$ 633K from CARB-X a global non-profit organisation, for the development of a preventive vaccine against Neisseria gonorrhoeae.
-
Intravacc launches new website with a wealth of scientific knowledge to elevate vaccine innovation
12/20/2023
Intravacc, a globally recognized pioneer and leader in translational vaccinology, announced the launch of its new website.
-
Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines
9/19/2023
Intravacc announced the publication of a scientific article of an in vitro alternative assay to the replace rabbit pyrogen test for vaccines.
-
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
9/14/2023
Intravacc, a leading Contract Development and Manufacturing Organization specializing in translational research and the development of preventive and therapeutic vaccines, has announced the publication of a review on the efficacy of intranasally administered outer membrane vesicle -based vaccines.
-
Mogrify and Astellas have forged a collaboration surrounding in vivo regenerative medicine approaches, while CardiNor inked a distribution deal with IBL-America.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
1/5/2022
Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, announced a partnership with Dutch Leiden University Medical Center to develop and evaluate a new nasal spray corona vaccine in a clinical phase I/II study.
-
Biopharma companies from around the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
BioSpace Global Roundup: Ayala Moves Forward with Desmoid Tumor Asset in Phase II/III Study
1/7/2021
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business. -
BioSpace Movers & Shakers, Nov. 6
11/6/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
BioSpace Global Roundup, Sept. 10
9/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Clinical Catch-Up: August 17-21
8/24/2020
It was a relatively quiet week for clinical trial news. Here’s a look. -
BioSpace Global Roundup, July 30
7/30/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
-
BioSpace Global Roundup, June 25
6/25/2020
Biopharma and life sciences companies provide updates on their pipelines and business plans. -
BioSpace Global Roundup, June 11
6/11/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Intravacc and EpiVax Team up in Development of COVID-19 Emerging Vaccine
6/2/2020
Intravacc, one of the world's leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, and EpiVax, a biotechnology company based in Providence with expertise in developing vaccines and therapeutics